Literature DB >> 13759334

Experimental evaluation of potential anticancer agents. IV. Host weight loss as it relates to false positives in drug evaluation.

W R LASTER, F M SCHABEL, H E SKIPPER, W S WILCOX, J R THOMSON.   

Abstract

Keywords:  ADENOCARCINOMA/experimental; ANTINEOPLASTIC AGENTS/pharmacology; SARCOMA/experimental

Mesh：

Substances：

Year:  1961        PMID： 13759334

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Authors:  Ramiro Vázquez; María E Riveiro; Lucile Astorgues-Xerri; Elodie Odore; Keyvan Rezai; Eugenio Erba; Nicolò Panini; Andrea Rinaldi; Ivo Kwee; Luca Beltrame; Mohamed Bekradda; Esteban Cvitkovic; Francesco Bertoni; Roberta Frapolli; Maurizio D'Incalci
Journal:  Oncotarget       Date:  2017-01-31

3.  PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.

Authors:  Lavinia Morosi; Marina Meroni; Maurizio D'Incalci; Roberta Frapolli; Paolo Ubezio; Ilaria Fuso Nerini; Lucia Minoli; Luca Porcu; Nicolò Panini; Marika Colombo; Barbara Blouw; David W Kang; Enrico Davoli; Massimo Zucchetti
Journal:  J Exp Clin Cancer Res       Date:  2021-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.